Cystic fibrosis at a Brazilian center of excellence: clinical and laboratory characteristics of 104 patients and their association with genotype and disease severity
OBJECTIVE: To identify the clinical, laboratory and radiographic characteristics of the cystic fibrosis patients under care at Universidade Estadual de Campinas (UNICAMP) in the last decade of the twentieth century, and to investigate the association of these characteristics with genotype and severity of the disease as measured by the Shwachman score. METHODS: Descriptive, retrospective and cross-sectional study of the patients assisted at UNICAMP hospital's Cystic Fibrosis Clinic from July 1990 to July 2000. RESULTS: One hundred and four patients were studied; 53.8% male; 93.3% Caucasian; 89.4% presented with respiratory symptoms; 59.6% presented with digestive symptoms; 5.8% had meconium ileus ; 4.8% had diabetes. The mean age at onset of symptoms was 3 months, and the mean age at diagnosis was 2 years and 4 months. At diagnosis, 69.9 and 56.6% of the patients had weight and height below 10th percentile, respectively; in 10.6%, sweat chloride was < 60 mEq/l. Staphylococcus aureus was found in 80.2%, Pseudomonas aeruginosa in 76.0%, and Burkholderia cepacia in 5.2%. deltaF508 homozygosis was observed in 18.75%, whereas 62.50% of the patients were deltaF508 heterozygous. A moderate/severe Shwachman score was found in 15.7%. Eighteen patients died in that period (17.3%). The mean age at death was 7 years and 8 months; median survival after diagnosis was 18 years and 4 months. Patients who have at least one deltaF508 mutation have more frequent alterations in fecal fat levels when compared to patients who do not have this mutation (p < 0.05). There were no differences in any parameter between deltaF508 homozygous and heterozygous patients. CONCLUSIONS: The clinical and laboratory characteristics of the 104 patients studied were similar to the characteristics described for patients in other countries. Exceptions are the higher age at diagnosis and lower survival. Our results support the recommendation for early diagnosis and the need for more treatment opportunities in the population of cystic fibrosis patients.OBJETIVO: Estudar as características clínicas, laboratoriais e radiográficas de pacientes fibrocísticos acompanhados na última década do século 20 na UNICAMP e verificar se existe associação com o genótipo e a gravidade da doença medida pelo escore de Shwachman. MÉTODOS: Estudo descritivo, retrospectivo e de corte transversal dos pacientes fibrocísticos acompanhados na UNICAMP, que tiveram atendimento entre julho de 1990 e julho de 2000. RESULTADOS: Foram estudados 104 pacientes: sexo masculino - 53,8%; raça caucasóide - 93,3%; comprometimento pulmonar - 89,4%, comprometimento digestivo - 59,6%; íleo meconial - 5,8%; diabetes melito - 4,8%; mediana da idade de início dos sintomas - 3 meses; mediana da idade no diagnóstico - 2 anos e 4 meses; 69,9 e 56,6% apresentavam peso e estatura abaixo do percentil 10, respectivamente, na época do diagnóstico; dosagem de cloro no suor < 60 mEq/l - 10,6%; colonização: S. aureus - 80,2%, P. aeruginosa - 76,0%, B. cepacia - 5,2%; delta F508 homozigoto - 18,75%, deltaF508 heterozigoto - 62,5%; escore de Shwachman moderado/grave - 15,7%. Foram a óbito 18 pacientes (17,3%); mediana de idade do óbito de 7 anos e 8 meses; sobrevida mediana após o diagnóstico no término do estudo de 18 anos e 4 meses. Os pacientes com a mutação deltaF508 apresentaram balanço de gordura nas fezes alterado com maior freqüência que os pacientes sem essa mutação (p < 0,05). Quando comparados os pacientes que apresentavam uma ou duas mutações deltaF508, nenhum parâmetro apresentou diferença estatisticamente significativa. CONCLUSÕES: As características clínicas e laboratoriais dos pacientes estudados foram semelhantes às descritas na população fibrocística de outros países, com algumas exceções, dentre as quais destacamos maior idade no diagnóstico e menor sobrevida. Desta forma, nossos dados permitem inferir que esforços para um diagnóstico precoce e maior oportunidade de tratamento necessitam ser dirigidos aos pacientes fibrocísticos